

**Announcement
21 May 2012****Coloplast – transactions in connection with share buy-back programme**

As mentioned in Announcement No. 2/2012 Coloplast has launched a share buy-back programme for up to DKK 1bn. The first part of the programme, of DKK 500m, is expected to take place during the period from 1 February 2012 to 30 September 2012. The second stage of the programme is expected to take place from 1 October, 2012 to 30 September, 2013.

Under the first of the programme the following transactions have been executed during the period 14 – 18 May 2012:

Date	Number of shares	Average buying price	Amount DKK
14.5.2012	8,904	1,021.39	9,094,457
15.5.2012	2,500	1,014.80	2,537,000
16.5.2012	8,322	1,012.32	8,424,527
17.5.2012	-	-	-
18.5.2012	-	-	-
Accumulated until now under the programme	348,016	958.88	333,707,264

Henceforth, Coloplast owns 2,883,177 own B shares of DKK 5 equal to 6.41% of the company's total share capital.

Share buy-back in the amount of DKK 166,292,736 remains under the first part of the programme.

For further information, please contact

Investors and analysts

Lene Skole
Executive Vice President, CFO
Tel. +45 4911 1700

Ian S.E. Christensen
Vice President, Investor Relations
Tel. +45 4911 1800/+45 4911 1301
Email: dkisec@coloplast.com

Henrik Nord
Investor Relations Manager
Tel. +45 4911 1800/+45 4911 3108
Email: dkhno@coloplast.com

Press and the media

Ulla Lundhus
Media Relations Manager
Tel. +45 4911 1929
Email: dkul@coloplast.com

This announcement is available in a Danish and an English-language version.
In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2012-5 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ around 7,500 people.